Cargando…

More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants

Detalles Bibliográficos
Autores principales:	Monach, Paul A, Branch-Elliman, Westyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science ;, The Lancet Pub. Group 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132782/ https://www.ncbi.nlm.nih.gov/pubmed/37119830 http://dx.doi.org/10.1016/S1473-3099(23)00274-8

Ejemplares similares

Moving towards a precision approach for prevention of severe COVID-19
por: Branch-Elliman, Westyn, et al.
Publicado: (2023)

Reconsidering ‘minimal risk’ to expand the repertoire of trials with waiver of informed consent for research
por: Monach, Paul A, et al.
Publicado: (2021)

Bringing New Meaning to the Term “Adaptive Trial”: Challenges of Conducting Clinical Research During the Coronavirus Disease 2019 Pandemic and Implications for Implementation Science
por: Branch-Elliman, Westyn, et al.
Publicado: (2020)

2656. Longitudinal Trends in Attributable Causes of Death Among US Veteran Patients with Documented SARS-CoV-2 Infection between January 2021 and March 2023
por: Trottier, Caitlin A, et al.
Publicado: (2023)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

The next ‘pandemic playbook’ needs to prioritize the needs of children—and a clear roadmap for opening schools
por: Branch-Elliman, Westyn, et al.
Publicado: (2023)

Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study
por: Li, Lucy L., et al.
Publicado: (2022)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?
por: Branch-Elliman, Westyn, et al.
Publicado: (2020)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
por: Takashita, Emi, et al.
Publicado: (2022)

Increased COVID-19 Breakthrough Infection Risk after Sars-Cov-2 Vaccine Boosting in Patients with Plasma Cell Disorders: A Large Nationwide Veterans Affairs Study
por: Fillmore, Nathanael R, et al.
Publicado: (2022)

Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study
por: Fillmore, Nathanael R., et al.
Publicado: (2022)

Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders
por: Fillmore, Nathanael R., et al.
Publicado: (2023)

T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant
por: Choi, Seong Jin, et al.
Publicado: (2022)

Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant
por: Zhang, Wei, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
por: Hu, Jie, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Liver injury caused by SARS-CoV-2 Delta and Omicron-variant in Taiwan
por: Jang, Tyng-Yuan
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation
por: La, Jennifer, et al.
Publicado: (2022)

Safety and efficacy of the Russian COVID-19 vaccine: more information needed
por: Bucci, Enrico, et al.
Publicado: (2020)

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
por: Bojkova, Denisa, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2
por: Antonelli, Michela, et al.
Publicado: (2022)

Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
por: Shen, Yaping, et al.
Publicado: (2022)

SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects – correspondence
por: Channabasappa, Nikhil K., et al.
Publicado: (2023)

Dynamic disease manifestations among individuals infected with SARS-CoV-2 Omicron variant
por: Wang, Peiqin, et al.
Publicado: (2023)

Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Automating surveillance for healthcare-associated infections: Rationale and current realities (Part I/III)
por: Shenoy, Erica S., et al.
Publicado: (2023)

Pandemic scientific data sharing recommendations: examining and re-imagining pre-print servers after the end of the world-wide emergency
por: Doron, Shira, et al.
Publicado: (2023)

Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
por: Blennow, Ola, et al.
Publicado: (2022)

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
por: Uriu, Keiya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qk0iit34ubjdd2nbod1knpi6ru